Recently listed Molbio Diagnostics delivered exceptional financial results for Q1FY27, with consolidated net profit surging 523% YoY to ₹52.7 crore. The diagnostics manufacturer's results reflect robust revenue growth, with total income rising fourfold to ₹411.5 crore from ₹100.5 crore in the corresponding period of FY25. The sharp improvement is largely attributable to the recognition of deferred export revenue, with management noting that export orders worth approximately ₹57 crore from Q4FY26 were pushed into Q1FY27 due to disruptions in the Gulf region. The company reported consolidated EBITDA of ₹103.7 crore against a loss of ₹14.5 crore in Q1FY25, with an EBITDA margin of 25.2% compared to (14.4%) previously.
During Q1FY27, Molbio Diagnostics demonstrated strong operational performance with significant capacity headroom. The company sold 164 devices and 62.4 lakh kits during the quarter, with device utilization at 42% and test kit utilization at 58%. Export revenue stood at approximately ₹67 crore, representing 16% of total revenue from operations, including the catch-up of deferred orders. Management highlighted that trailing 12-month receivable days remained stable at 87 days in June versus 86 days in March, while inventory days improved to 230 days from 280 days. The company maintains that its business has a non-linear revenue profile, advising investors to assess performance on a full-year basis.
Despite the strong quarterly results, Molbio Diagnostics shares experienced a sharp decline, dropping 8.8% to ₹1,229.65 on September 16, following profit booking after significant gains. According to reports from LiveMint, the stock declined for the second consecutive session, falling as much as 8.8% to hit an intraday low of ₹1,229.65 per share on the BSE. The stock, which made its market debut on August 17 this year, is currently up more than 50% from its issue price of ₹807. The shares listed at ₹980, representing a 21.44% premium over the IPO price of ₹807. The recent correction follows an exceptionally strong run after listing, with shares gaining 75% in the last 1 month and touching their 52-week high of ₹1,686.50 on September 11.
During the quarter, Molbio Diagnostics strengthened its subsidiary portfolio by increasing its stake in Prognosys Medical Systems Private Limited from 65.47% to 70.00% by acquiring an additional 4.53% stake. Earlier in FY26, the company had converted its associate interest in OptraSCAN Inc. into a subsidiary by increasing its holding to 60%, effective November 1, 2025. OptraScan recently received US FDA clearance for its end-to-end digital pathology solution in July 2026, with management stating that conversations have begun with large laboratory chains in the US, with meaningful financial contribution expected from FY8 onwards. Management provided guidance for top-line growth of roughly 25% for FY27 and an EBITDA margin of 24% to 25%.
The company disclosed an ongoing survey under Section 133A of the Income-tax Act, 1961, with the tax department raising demands aggregating to ₹208.71 million plus interest and penalty for assessment years 2020-21 to 2024-25. Molbio has appealed to the Commissioner of Income Tax (Appeals) and paid ₹78.95 million under protest as of June 30, 2026. Management expressed confidence in a favorable outcome and made no adjustments in the financial results. The company's deployment of net issue proceeds is underway, with approximately ₹72 crore allocated to automation and about ₹105 crore to build an integrated R&D center in Bengaluru. For the full year, Prognosys is expected to deliver margins closer to 19% EBITDA, while OptraScan is not expected to be profitable in FY27.
